Davy Vancampfort1,2, Alex J Mitchell3,4, Marc De Hert1, Pascal Sienaert1, Michel Probst1, Roselien Buys2, Brendon Stubbs5. 1. 1UPC KU Leuven, Campus Kortenberg, KU Leuven, Department of Neurosciences, Belgium. 2. KU Leuven, Department of Rehabilitation Sciences, Leuven, Belgium. 3. Department of Psycho-Oncology, Leicestershire Partnership Trust, Leicester, UK. 4. Department of Cancer and Molecular Medicine, University of Leicester, Leicester, UK. 5. School of Health and Social Care, University of Greenwich, London, UK.
Abstract
BACKGROUND: Patients with depression may be at increased risk of type 2 diabetes mellitus (T2DM), which is a risk factor for cardiovascular diseases and premature mortality. We aimed to clarify the prevalence and predictors of T2DM in patients with major depressive disorder (MDD) and where possible compare the prevalence of T2DM in those with MDD versus general population controls. METHODS: We searched major electronic databases until December 2014 for studies reporting T2DM prevalence in patients with MDD. Two independent authors extracted data and completed methodological quality appraisal in accordance with the meta-analysis of observational studies in epidemiology (MOOSE) guidelines. A random effects meta-analysis was utilized. RESULTS: The initial electronic database search resulted in 145 valid hits and 16 publications with clearly defined MDD (n = 15,8834; 31% male; mean age = 39-78 years) met the eligibility criteria. The overall prevalence of T2DM was 8.7% (95% confidence interval [CI] = 7.3-10.2%). Mean age of the MDD sample predicted a higher prevalence of T2DM (β = 0.0411; 95% CI = 0.0032-0.079, P = .03; R² = .22). A comparative meta-analysis revealed people with MDD (n = 154,366) had a higher risk of T2DM versus general controls (n = 2,098,063; relative risk [RR] = 1.49; 95% CI = 1.29-1.72; P < 0.001, N = 10). The RR (N = 3) focusing on age- and gender-matched general population controls (n = 103,555) was 1.36 (95% CI = 1.28-1.44; P < 0.001, n [MDD] = 10,895). CONCLUSIONS: T2DM is significantly more common in people with MDD compared with the general population. The current meta-analysis indicates that action is needed in order to curb the diabetes epidemic in this high-risk population.
BACKGROUND:Patients with depression may be at increased risk of type 2 diabetes mellitus (T2DM), which is a risk factor for cardiovascular diseases and premature mortality. We aimed to clarify the prevalence and predictors of T2DM in patients with major depressive disorder (MDD) and where possible compare the prevalence of T2DM in those with MDD versus general population controls. METHODS: We searched major electronic databases until December 2014 for studies reporting T2DM prevalence in patients with MDD. Two independent authors extracted data and completed methodological quality appraisal in accordance with the meta-analysis of observational studies in epidemiology (MOOSE) guidelines. A random effects meta-analysis was utilized. RESULTS: The initial electronic database search resulted in 145 valid hits and 16 publications with clearly defined MDD (n = 15,8834; 31% male; mean age = 39-78 years) met the eligibility criteria. The overall prevalence of T2DM was 8.7% (95% confidence interval [CI] = 7.3-10.2%). Mean age of the MDD sample predicted a higher prevalence of T2DM (β = 0.0411; 95% CI = 0.0032-0.079, P = .03; R² = .22). A comparative meta-analysis revealed people with MDD (n = 154,366) had a higher risk of T2DM versus general controls (n = 2,098,063; relative risk [RR] = 1.49; 95% CI = 1.29-1.72; P < 0.001, N = 10). The RR (N = 3) focusing on age- and gender-matched general population controls (n = 103,555) was 1.36 (95% CI = 1.28-1.44; P < 0.001, n [MDD] = 10,895). CONCLUSIONS: T2DM is significantly more common in people with MDD compared with the general population. The current meta-analysis indicates that action is needed in order to curb the diabetes epidemic in this high-risk population.
Authors: Rodrigo B Mansur; Gabriel R Fries; Alisson P Trevizol; Mehala Subramaniapillai; Julie Lovshin; Kangguang Lin; Maj Vinberg; Roger C Ho; Elisa Brietzke; Roger S McIntyre Journal: Eur Neuropsychopharmacol Date: 2018-11-06 Impact factor: 4.600
Authors: Shuichi Suetani; Sukanta Saha; Adam Milad; Elizabeth Eakin; James G Scott; John J McGrath Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2016-11-10 Impact factor: 4.328
Authors: Stephen M Shortell; Bing Ying Poon; Patricia P Ramsay; Hector P Rodriguez; Susan L Ivey; Thomas Huber; Jeremy Rich; Tom Summerfelt Journal: J Gen Intern Med Date: 2017-02-03 Impact factor: 5.128
Authors: Jeffrey L Birk; Ian M Kronish; Nathalie Moise; Louise Falzon; Sunmoo Yoon; Karina W Davidson Journal: Health Psychol Date: 2019-04-22 Impact factor: 4.267
Authors: Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen Journal: World Psychiatry Date: 2020-10 Impact factor: 49.548
Authors: Davy Vancampfort; Christoph U Correll; Britta Galling; Michel Probst; Marc De Hert; Philip B Ward; Simon Rosenbaum; Fiona Gaughran; John Lally; Brendon Stubbs Journal: World Psychiatry Date: 2016-06 Impact factor: 49.548
Authors: Deborah S Hasin; Aaron L Sarvet; Jacquelyn L Meyers; Tulshi D Saha; W June Ruan; Malka Stohl; Bridget F Grant Journal: JAMA Psychiatry Date: 2018-04-01 Impact factor: 21.596
Authors: Brendon Stubbs; Davy Vancampfort; Simon Rosenbaum; Philip B Ward; Justin Richards; Michael Ussher; Felipe B Schuch Journal: Sports Med Date: 2016-05 Impact factor: 11.136